Role of Oral Lactoferrin in Prevention of Recurnt Bacterial Vaginosis in Pregnancy
Bacterial Vaginosis | Vaginal | Microbiology
About this trial
This is an interventional treatment trial for Bacterial Vaginosis | Vaginal | Microbiology
Eligibility Criteria
Inclusion Criteria: Pregnant women of age group 20-37 years. Primigravida. 28-40 week gestation. History of receurent bacterial vaginosis . Exclusion Criteria: Multiple gestations. Multiparity. Medical disorders as: Diabetes mellitus. Chronic hypertension. Endocrinal diseases. Autoimmune diseases. Renal diseases. Blood diseases. Allergy to lactoferrin .
Sites / Locations
- Rania Samy ezzatRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
study group
control group
study group receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotinR). During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.
not recieving lactoferrin